Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates

Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges

(2017)   SWISS MEDICAL WEEKLY

Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine

(2015) Yan Zhou et al.   CURRENT OPINION IN IMMUNOLOGY

Heterologous Prime-Boost Regimens with a Recombinant Chimpanzee Adenoviral Vector and Adjuvanted F4 Protein Elicit Polyfunctional HIV-1-Specific T-Cell Responses in Macaques

(2015) Clarisse Lorin et al.   PLoS One

Vaccines for the 21st century

(2014) I. Delany et al.   EMBO Molecular Medicine

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

(2014) Daphne A Stanley et al.   NATURE MEDICINE

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

(2014) L. Swadling et al.   Science Translational Medicine

Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses

(2013) Shih-Chang Lin et al.   Biotechnology Journal

Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults

(2013) Peter Hayes et al.   Clinical and Vaccine Immunology

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus

(2013) Anne Fournillier et al.   JOURNAL OF INFECTIOUS DISEASES

DNA Priming Prior to Inactivated Influenza A(H5N1) Vaccination Expands the Antibody Epitope Repertoire and Increases Affinity Maturation in a Boost-Interval–Dependent Manner in Adults

(2013) Surender Khurana et al.   JOURNAL OF INFECTIOUS DISEASES

Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect

(2013) Julie E. Ledgerwood, Kathryn Zephir, Zonghui Hu, Chih-Jen Wei, LeeJah Chang, Mary E. Enama, Cynthia S. Hendel, Sandra Sitar, Robert T. Bailer, Richard A. Koup, John R. Mascola, Gary J. Nabel, Barney S. Graham et al.   JOURNAL OF INFECTIOUS DISEASES

Robust Immunity to an Auxotrophic Mycobacterium bovis BCG-VLP Prime-Boost HIV Vaccine Candidate in a Nonhuman Primate Model

(2013) G. K. Chege et al.   JOURNAL OF VIROLOGY

Prime/Boost Immunization with DNA and Adenoviral Vectors Protects from Hepatitis D Virus (HDV) Infection after Simultaneous Infection with HDV and Woodchuck Hepatitis Virus

(2013) M. Fiedler et al.   JOURNAL OF VIROLOGY

Technologies for enhanced efficacy of DNA vaccines

(2012) Fadi Saade et al.   Expert Review of Vaccines

A Triclade DNA Vaccine Designed on the Basis of a Comprehensive Serologic Study Elicits Neutralizing Antibody Responses against All Clades and Subclades of Highly Pathogenic Avian Influenza H5N1 Viruses

(2012) F. Zhou et al.   JOURNAL OF VIROLOGY

Broader Neutralizing Antibodies against H5N1 Viruses Using Prime-Boost Immunization of Hyperglycosylated Hemagglutinin DNA and Virus-Like Particles

(2012) Shih-Chang Lin et al.   PLoS One

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets

(2011) Mario Roederer et al.   CYTOMETRY PART A

HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable

(2011) S. C. De Rosa et al.   JOURNAL OF IMMUNOLOGY

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

(2011) Paul A. Goepfert et al.   JOURNAL OF INFECTIOUS DISEASES

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

(2011) T. W. Geisbert et al.   JOURNAL OF VIROLOGY

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

(2011) Julie E Ledgerwood et al.   LANCET INFECTIOUS DISEASES

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

(2011) Nancy J Sullivan et al.   NATURE MEDICINE

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial

(2011) Beryl A. Koblin et al.   PLoS One

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

(2011) Gavin J. Churchyard et al.   PLoS One

DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4+ T cells, but few subdominant epitope-specific CD8+ T cells

(2011) Lara Vojnov et al.   VACCINE

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania

(2011) Muhammad Bakari et al.   VACCINE

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

(2011) Lilin Lai et al.   VACCINE

DNA vaccines: an historical perspective and view to the future

(2010) Margaret A. Liu   IMMUNOLOGICAL REVIEWS

Robust Vaccine-Elicited Cellular Immune Responses in Breast Milk following Systemic Simian Immunodeficiency Virus DNA Prime and Live Virus Vector Boost Vaccination of Lactating Rhesus Monkeys

(2010) A. B. Wilks et al.   JOURNAL OF IMMUNOLOGY

A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)

(2010) Hannah Kibuuka et al.   JOURNAL OF INFECTIOUS DISEASES

Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates

(2010) T. W. Geisbert et al.   JOURNAL OF VIROLOGY

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses

(2010) Richard A. Koup et al.   PLoS One

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa

(2010) Walter Jaoko et al.   PLoS One

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species

(2010) Lisa E. Hensley et al.   PLoS Pathogens

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

(2009) Nancy J. Sullivan et al.   NATURE REVIEWS MICROBIOLOGY

A prime–boost immunisation regimen using recombinant BCG and Pr55gag virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons

(2009) Gerald K. Chege et al.   VACCINE

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

(2009) Lindvi Gudmundsdotter et al.   VACCINE